IN2014MN01940A - - Google Patents

Download PDF

Info

Publication number
IN2014MN01940A
IN2014MN01940A IN1940MUN2014A IN2014MN01940A IN 2014MN01940 A IN2014MN01940 A IN 2014MN01940A IN 1940MUN2014 A IN1940MUN2014 A IN 1940MUN2014A IN 2014MN01940 A IN2014MN01940 A IN 2014MN01940A
Authority
IN
India
Prior art keywords
getting
risk
cardiovascular event
level
neurotensin
Prior art date
Application number
Other languages
English (en)
Inventor
Andreas Bergmann
Olle Melander
Original Assignee
Sphingotec Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sphingotec Gmbh filed Critical Sphingotec Gmbh
Publication of IN2014MN01940A publication Critical patent/IN2014MN01940A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN1940MUN2014 2012-03-08 2013-03-08 IN2014MN01940A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261608376P 2012-03-08 2012-03-08
EP12158678 2012-03-08
EP12165057 2012-04-20
PCT/EP2013/054799 WO2013132088A1 (fr) 2012-03-08 2013-03-08 Méthode de prédiction du risque de survenue d'un événement cardiovasculaire chez un sujet de sexe féminin

Publications (1)

Publication Number Publication Date
IN2014MN01940A true IN2014MN01940A (fr) 2015-07-10

Family

ID=49115969

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1940MUN2014 IN2014MN01940A (fr) 2012-03-08 2013-03-08

Country Status (7)

Country Link
US (1) US20150118236A1 (fr)
EP (1) EP2823318B1 (fr)
JP (1) JP6431373B2 (fr)
CN (1) CN103308673B (fr)
IN (1) IN2014MN01940A (fr)
RU (1) RU2652304C2 (fr)
WO (1) WO2013132088A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160097781A1 (en) * 2014-10-01 2016-04-07 Sphingotec Gmbh Method for stratifying a female subject for hormone replacement therapy
SG10202003170YA (en) 2015-02-27 2020-05-28 Sphingotec Gmbh A method for predicting the risk of obesity in a subject
JP7411546B2 (ja) 2017-10-24 2024-01-11 シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 初回心血管イベントの予測のためのセレノプロテインｐ
CN109678958B (zh) * 2019-01-31 2022-03-18 重庆探生科技有限公司 一种人NT-proBNP特异性重组羊单克隆抗体及其制备方法和应用
RU2718285C1 (ru) * 2019-05-31 2020-04-01 федеральное государственное бюджетное образовательное учреждение высшего образования "Новосибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО НГМУ Минздрава России) Способ прогнозирования риска развития инсульта у мужчин, работающих в условиях воздействия общей вибрации
WO2022101937A1 (fr) * 2020-11-12 2022-05-19 Shah Komal Dispositif intégré de capture et d'analyse de données de santé pour évaluation, diagnostic et pronostic de l'insuffisance cardiaque

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU634716B2 (en) 1988-08-01 1993-03-04 Ciba Corning Diagnostics Corp. Method for detection of an analyte using acridinium esters and liposomes
US6352862B1 (en) * 1989-02-17 2002-03-05 Unilever Patent Holdings B.V. Analytical test device for imuno assays and methods of using same
US5736343A (en) * 1995-08-18 1998-04-07 Landry; Donald Detection of organic compounds through regulation of antibody-catalyzed reactions
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
WO2003016910A1 (fr) * 2001-08-20 2003-02-27 Biosite, Inc. Marqueurs diagnostiques d'ictus et de lesions cerebrales et procedes d'utilisation de ces marqueurs
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
AU2002323501C1 (en) 2001-08-30 2010-04-29 Biorexis Technology, Inc Modified transferrin fusion proteins
DK1531791T3 (da) 2002-06-07 2010-11-01 Dyax Corp Forebyggelse og begrænsning af iskæmi
US7634360B2 (en) * 2003-09-23 2009-12-15 Prediction Sciences, LL Cellular fibronectin as a diagnostic marker in stroke and methods of use thereof
CA2543360A1 (fr) 2003-10-24 2005-05-06 Joost A. Kolkman Multimeres et monomeres comprenant des domaines de recepteur de lipoproteines de basse densite de classe a et egf
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
EP1759214B1 (fr) * 2004-06-15 2013-04-24 F.Hoffmann-La Roche Ag Utilisation d'hormones cardiaques pour le diagnostic des risques de complications cardiovasculaires dues a une intoxication liee a un medicament cardiotoxique
WO2006032436A2 (fr) 2004-09-21 2006-03-30 Nascacell Technologies Ag. Utilisation de microproteines en tant qu'inhibiteurs d'une tryptase
DE102005003687A1 (de) * 2005-01-26 2006-07-27 Sphingo Tec Gmbh Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation
EP2231860B1 (fr) 2007-12-19 2011-10-05 Affibody AB Polypeptide dérivé d'une protéine et se liant au pdgf
WO2010060748A1 (fr) 2008-11-03 2010-06-03 Molecular Partners Ag Protéines de liaison inhibant l’interaction du récepteur vegf-a
ES2538002T3 (es) 2009-01-07 2015-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Métodos para el tratamiento, la evaluación pronóstica y la detección de cáncer de mama
EP2427764B1 (fr) * 2009-05-05 2017-07-26 B.R.A.H.M.S GmbH Stratification à base d'hormone vasoactive de patients souffrant de maladies liées à la fonction ou à un dysfonctionnement endothélial
CA2772162C (fr) 2009-08-27 2018-05-22 Covagen Ag Fynomer anti-il-17a et leurs usages medicaux
US8846414B2 (en) * 2009-09-29 2014-09-30 Advanced Liquid Logic, Inc. Detection of cardiac markers on a droplet actuator
US20120301393A1 (en) 2009-12-14 2012-11-29 Scil Proteins Gmbh Modified ubiquitin proteins having a specific binding activity for the extradomain b of fibronectin
CN105949301B (zh) 2010-06-08 2020-03-27 皮里斯制药有限公司 结合IL-4受体α的泪脂质运载蛋白突变蛋白

Also Published As

Publication number Publication date
EP2823318A1 (fr) 2015-01-14
CN103308673A (zh) 2013-09-18
RU2652304C2 (ru) 2018-04-25
WO2013132088A4 (fr) 2013-11-07
WO2013132088A1 (fr) 2013-09-12
JP6431373B2 (ja) 2018-11-28
EP2823318B1 (fr) 2016-08-10
US20150118236A1 (en) 2015-04-30
CN103308673B (zh) 2017-05-31
RU2014140430A (ru) 2016-04-27
JP2015511007A (ja) 2015-04-13

Similar Documents

Publication Publication Date Title
IN2014MN01940A (fr)
HK1219010A1 (zh) 基於指紋來檢測廣告的系統和方法
EP2576837A4 (fr) Biomarqueurs d'acides nucléiques circulants associés au cancer de la prostate
BR112013032183A2 (pt) sistema e método de avaliação de recursos
WO2014200912A3 (fr) Procédés mathématiques pour la détermination du clivage de la peptidase
IL230896B (en) Micro-rna biological markers for use in detecting the presence or risk of a lung tumor or an aggressive lung tumor
NZ630421A (en) Biomarkers predictive for clinical response for glatiramer acetate
MX370790B (es) Acoplamiento roscado para tuberia de acero.
WO2013159872A8 (fr) Biomarqueurs pour le diagnostic, le pronostic, l'évaluation et la stratification thérapeutique d'une syncope
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
WO2012135227A3 (fr) Procédés et systèmes pour évaluer l'exposition à des métaux lourds
FR2992620B1 (fr) Train et procede de determination de la composition d'un tel train en securite
WO2016066862A3 (fr) Méthode de prédiction du risque d'obésité chez un sujet
MX2022013471A (es) Metodo y composiciones de deteccion y cuantificacion de acido nucleico.
IN2014MN01936A (fr)
FR2996192B1 (fr) Procede de determination de l'etat d'usure d'une piece et d'information d'un client
MX2015015328A (es) Deteccion de grietas de borde.
PL3289096T3 (pl) Sposób prognozowania i/lub diagnozowania choroby na podstawie próbki tkanki tłuszczowej
IN2015DN01646A (fr)
IN2014MN01937A (fr)
FR2996250B1 (fr) Procede d'identification et/ou de suivi de la deformation d'une piece de turbomachine
WO2013106851A3 (fr) Syncolline, triacylglycérol lipase pancréatique et autres biomarqeurs du diabète
WO2014023952A3 (fr) Prévention et traitement de l'ostéoarthrite
TR201901828T4 (tr) Bir kişide kanser olma veya kanser tanısı konma riskinin öngörüsü için bir usul.
EP3004846C0 (fr) Trousse permettant de détecter un micro-arn extrait d'un échantillon de fluide corporel et procédé pour sa détection